Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.

Abstract:

:Because of delays in the manufacturing of the 2000-2001, trivalent inactivated influenza vaccine in the US, there were concerns that there might be shortages of vaccine supply in the US. Therefore, we conducted a prospective, randomized, open-label, multicenter trial at six academic medical centers in the US, to evaluate the immunogenicity of a half dose of inactivated vaccine in healthy adults. Healthy adults between the ages of 18 and 49 were randomized to receive either a full 0.5ml (15.5 microg of each HA antigen) dose or a 0.25ml (7.75 microg of each HA antigen) dose of the 2000-2001 trivalent inactivated influenza vaccine by intramuscular injection. Sera were obtained for assessment of hemagglutination-inhibiting antibody to each of the three strains contained in the vaccine before and 21 days after vaccination. The proportions of individuals achieving a post-vaccination titer of > or =1:40, the geometric mean titers (GMTs) of post-vaccination antibody, and the proportions of individuals with a four-fold or greater increase in antibody were lower for all three strains in those receiving 0.25ml of vaccine compared to those receiving 0.5ml. However, the differences were small for all three antigens. The upper 95% confidence limits for differences between 0.25 and 0.5ml doses were less than 20% for rates of achieving a titer of > or =1:40 and four-fold response, and less than 1.5 for the ratios of GMTs between dose groups, for all three vaccine antigens. These results suggest that when vaccine is in short supply, a strategy using a half dose in healthy adults could increase the number of people vaccinated with relatively little adverse impact on vaccine immunogenicity.

journal_name

Vaccine

journal_title

Vaccine

authors

Treanor J,Keitel W,Belshe R,Campbell J,Schiff G,Zangwill K,Wolff M,Klimov A,Levandowski R,Lambert L

doi

10.1016/s0264-410x(01)00440-6

subject

Has Abstract

pub_date

2002-01-15 00:00:00

pages

1099-105

issue

7-8

eissn

0264-410X

issn

1873-2518

pii

S0264410X01004406

journal_volume

20

pub_type

临床试验,杂志文章,随机对照试验

相关文献

VACCINE文献大全
  • HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.

    abstract:INTRODUCTION:In 2009, girls-only HPV16/18 vaccination was introduced in the Netherlands which has achieved 46-61% uptake. Heterosexual men have benefitted from herd protection, but it is unknown whether men who have sex with men (MSM) also benefit from herd effects of the girls-only HPV16/18 vaccination program. Becaus...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.03.002

    authors: Woestenberg PJ,van Benthem BHB,Bogaards JA,King AJ,van der Klis FRM,Pasmans H,Leussink S,van der Sande MAB,Hoebe CJPA,Medical Microbiological Laboratories, the Public Health Services.

    更新日期:2020-04-09 00:00:00

  • Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis.

    abstract::Pharmacological manipulation of the balance between pro- and anti-inflammatory mediators emerges as a key aspect of a successful treatment of sepsis. A murine model of septic shock was developed and chosen conjugates (1a, 1b, 8a, 8c) and analogs (T2) of muramyl dipeptide and tuftsin were tested in this model as prospe...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.11.017

    authors: Wardowska A,Dzierzbicka K,Szaryńska M,Dabrowska-Szponar M,Wiśniewska K,Myśliwski A,Trzonkowski P

    更新日期:2009-01-14 00:00:00

  • Critical issues in cancer vaccine trial design.

    abstract::As the clinical experience with cancer vaccines and cancer immunotherapy increases, there are important lessons that can be learned from the successes and failures of past trials. Many lessons affect the design and conduct of clinical trials themselves. Appropriate patient selection, clinical trial design, immunologic...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.09.019

    authors: Clifton GT,Kohrt HE,Peoples GE

    更新日期:2015-12-16 00:00:00

  • Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study.

    abstract:BACKGROUND AND PURPOSE:Varicella disease is a risk factor for pediatric Arterial Ischemic Stroke (AIS). Isolated case reports have emerged suggesting that varicella vaccination may also pose a risk for AIS. METHODS:This retrospective population-based cohort study assessed the risk of AIS in children who received a var...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.04.012

    authors: MacDonald SE,Dover DC,Hill MD,Kirton A,Simmonds KA,Svenson LW

    更新日期:2018-05-11 00:00:00

  • Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015.

    abstract:BACKGROUND:Little is known about inactivated influenza vaccine effectiveness (IVE) in preventing very severe disease, including influenza-associated intensive care unit (ICU) admissions. METHODS:The Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) project enrolled adults (age...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.07.028

    authors: Thompson MG,Pierse N,Sue Huang Q,Prasad N,Duque J,Claire Newbern E,Baker MG,Turner N,McArthur C,SHIVERS investigation team.

    更新日期:2018-09-18 00:00:00

  • Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.

    abstract::The great clinical and economical impact of Toxoplasma gondii infections makes the development of an effective vaccine for controlling toxoplasmosis an extremely important aim. In the presented study, we evaluate the protective and immunogenic properties of three recombinant subunit vaccines composed of rROP2+rGRA4+rS...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.11.002

    authors: Dziadek B,Gatkowska J,Brzostek A,Dziadek J,Dzitko K,Grzybowski M,Dlugonska H

    更新日期:2011-01-17 00:00:00

  • Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults.

    abstract:INTRODUCTION:Determining vaccine responsiveness is challenging in immune compromised individuals. The microbead array (MBA) assay is a rapid, inexpensive test for evaluating influenza vaccine immunogenicity. MBA performance was compared to hemagglutination inhibition assay (HAI) utilizing HIV seropositive vaccine recip...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2016.05.020

    authors: Thorne A,Chowdhury F,Singer J,Keynan Y,Fowke KR,Cooper C,CIHR Canadian HIV Trials Network (CTN) Influenza Vaccine Research Group.

    更新日期:2016-06-30 00:00:00

  • Expression of HIV-1 envelope gene by recombinant avipox viruses.

    abstract::Recombinant canarypox (CP) and fowlpox (FP) viruses that contained two forms of the HIV-1 (SF2 strain) env gene were engineered and their expression analysed in chick, simian and human cells. These vectors can efficiently replicate in avian but not in mammalian cells, in which infection is abortive. The two forms, con...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90180-5

    authors: Radaelli A,De Giuli Morghen C

    更新日期:1994-09-01 00:00:00

  • Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013.

    abstract:INTRODUCTION:Two types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced by a domestic manufacturer in China, was prequalified by WHO in 2013. We assessed the safety of JE vaccines in China duri...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.05.021

    authors: Wu W,Liu D,Li K,Nuorti JP,Nohynek HM,Xu D,Ye J,Zheng J,Wang H

    更新日期:2017-06-22 00:00:00

  • Measles seroprevalence in Chiradzulu district, Malawi: Implications for evaluating vaccine coverage.

    abstract:INTRODUCTION:Self-reported measles vaccination coverage is frequently used to inform vaccination strategies in resource-poor settings. However, little is known to what extent this is a reliable indicator of underlying seroprotection, information that could provide guidance ensuring the success of measles control and el...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.07.007

    authors: Polonsky JA,Juan-Giner A,Hurtado N,Masiku C,Kagoli M,Grais RF

    更新日期:2015-08-26 00:00:00

  • Risk factors for measles in children aged 8 months-14 years in China after nationwide measles campaign: A multi-site case-control study, 2012-2013.

    abstract:INTRODUCTION:Endemic measles persists in China, despite >95% reported coverage of two measles-containing vaccine doses and nationwide campaign that vaccinated more than 100 million children in 2010. In 2011, almost half of the 9943 measles cases in China occurred in children eligible for measles vaccination. We conduct...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2016.02.005

    authors: Hao L,Ma C,Wannemuehler KA,Su Q,An Z,Cairns L,Quick L,Rodewald L,Liu Y,He H,Xu Q,Ma Y,Yu W,Zhang N,Li L,Wang N,Luo H,Wang H,Gregory CJ

    更新日期:2016-12-12 00:00:00

  • Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998-2004.

    abstract::The influenza immunization program in North America has been primarily designed to provide direct benefit to vaccinated individuals at highest risk of serious influenza outcomes. Some evidence suggests that immunization of certain age groups may also extend indirect protective benefit to vulnerable populations. Our go...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.11.090

    authors: Sebastian R,Skowronski DM,Chong M,Dhaliwal J,Brownstein JS

    更新日期:2008-03-04 00:00:00

  • Vaccine adverse events in a safety net healthcare system and a managed care organization.

    abstract:BACKGROUND:The Institute of Medicine, in a 2013 report, recommended that the Vaccine Safety Datalink (VSD) expand collaborations to include more diversity in the study population. Kaiser Permanente Colorado (KPCO), an established VSD site, partnered with Denver Health (DH), an integrated safety net healthcare system, t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.01.017

    authors: Narwaney KJ,Breslin K,Ross CA,Shoup JA,Wain KF,Weintraub ES,McNeil MM,Hambidge SJ

    更新日期:2017-03-01 00:00:00

  • Epidemiology and transmission dynamics of the 1918-19 pandemic influenza in Florence, Italy.

    abstract::To investigate the 1918/19 influenza pandemic daily number of new hospitalizations in the only hospital in Florence (Central Italy) were analyzed. In order to describe the transmission dynamics of the 1918/1919 pandemic influenza a compartmental epidemic model was used. Model simulations show a high level of agreement...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.02.049

    authors: Rizzo C,Ajelli M,Merler S,Pugliese A,Barbetta I,Salmaso S,Manfredi P

    更新日期:2011-07-22 00:00:00

  • Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

    abstract:BACKGROUND:Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2013.08.064

    authors: Treanor JJ,Essink B,Hull S,Reed S,Izikson R,Patriarca P,Goldenthal KL,Kohberger R,Dunkle LM

    更新日期:2013-11-19 00:00:00

  • Leptospiral immunoglobulin-like proteins elicit protective immunity.

    abstract::The identification of new vaccine candidates for leptospirosis is of great interest. This paper describes the identification of two homologous immunogenic proteins, LigA-m and LigB-m, of Leptospira interrogans serovar manilae strain UP-MMC-NIID, which show strong similarity with LigA found recently in L. interrogans s...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.10.007

    authors: Koizumi N,Watanabe H

    更新日期:2004-03-29 00:00:00

  • Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.

    abstract:BACKGROUND:To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). METHODS:Based on variability in diseas...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.084

    authors: Constenla D,Liu T

    更新日期:2019-12-10 00:00:00

  • Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques.

    abstract::Herpes B virus (Cercopithecine herpesvirus 1) is endemic in captive macaque populations and poses a serious threat to humans who work with macaques or their tissues. A vaccine that could prevent or limit B virus infection in macaques would lessen occupational risk. To that end, a DNA vaccine plasmid expressing the B v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00232-8

    authors: Loomis-Huff JE,Eberle R,Lockridge KM,Rhodes G,Barry PA

    更新日期:2001-09-14 00:00:00

  • RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.

    abstract::Ricin is a plant toxin that is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax), which contains mutations in both known toxic sites, has no residual toxicity at doses at least 800 times the immunogenic dose. RiVax without adjuvant given intramuscularly (i.m.) protected mice against intraperitonea...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.08.018

    authors: Smallshaw JE,Richardson JA,Vitetta ES

    更新日期:2007-10-16 00:00:00

  • Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.

    abstract::The use of viral vectors in heterologous prime-boost regimens to induce potent T cell responses in addition to humoral immunity is a promising vaccination strategy in the fight against malaria. We conducted an open-label, first-in-human, controlled Phase I study evaluating the safety and immunogenicity of Matrix-M adj...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.09.028

    authors: Venkatraman N,Anagnostou N,Bliss C,Bowyer G,Wright D,Lövgren-Bengtsson K,Roberts R,Poulton I,Lawrie A,Ewer K,V S Hill A

    更新日期:2017-10-27 00:00:00

  • Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.

    abstract::Since smallpox eradication by the WHO during the 1980s, potency of new vaccines is compared to vaccines that were used during the eradication campaign. In this work we characterize the tail scarification technique in mice as a model for scarification in humans. Similar to humans, mice develop "clinical take" which is ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.09.023

    authors: Melamed S,Paran N,Katz L,Ben-Nathan D,Israely T,Schneider P,Levin R,Lustig S

    更新日期:2007-11-07 00:00:00

  • Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination.

    abstract::The Vaccine Adverse Event Reporting System (VAERS) is the US passive surveillance system monitoring vaccine safety. A major limitation of VAERS is the lack of denominator data (number of doses of administered vaccine), an element necessary for calculating reporting rates. Empirical Bayesian data mining, a data analysi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00237-7

    authors: Niu MT,Erwin DE,Braun MM

    更新日期:2001-09-14 00:00:00

  • Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection.

    abstract::Rhodococcus equi causes severe pneumonia in foals and has recently gained attention as a significant opportunistic pathogen in immunocompromised humans. However, no effective vaccine to prevent rhodococcosis is currently available. In this study, we have engineered the food-grade bacterium Lactococcus lactis to secret...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.10.026

    authors: Cauchard S,Bermúdez-Humarán LG,Blugeon S,Laugier C,Langella P,Cauchard J

    更新日期:2011-12-09 00:00:00

  • Classification of measles cases from 2014 to 2018: Implications for progress towards measles elimination in China.

    abstract::Measles incidence has decreased dramatically in China due to the implement of measles-containing vaccine (MCV). However, a measles epidemic caused resurgence recently, even among vaccinated individuals. To evaluate the effectiveness of current immunization programs and discuss initiatives for the next step in measles ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.03.049

    authors: Cui A,Zhang Y,Zhu Z,Wang H,Mao N,Song J,Xu W

    更新日期:2020-05-08 00:00:00

  • Mapping financial flows for immunisation in Uganda 2009/10 and 2010/11: New insights for methodologies and policy.

    abstract:BACKGROUND:The Global Vaccine Action Plan highlights the need for immunisation programmes to have sustainable access to predictable funding. A good understanding of current and future funding needs, commitments, and gaps is required to enhance planning, improve resource allocation and mobilisation, and to avoid funding...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.12.053

    authors: Guthrie T,Zikusooka C,Kwesiga B,Abewe C,Lagony S,Schutte C,Marinda E,Humphreys K,Motlogelwa K,Nombewu ZC,Brenzel L,Kinghorn A

    更新日期:2015-05-07 00:00:00

  • Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

    abstract:BACKGROUND:Concern arose in 2010 that reactogenicity, particularly febrile seizures, to influenza A/H1N1-containing 2010-2011 trivalent seasonal inactivated influenza vaccine (TIV) could occur in young children who had been previously immunized and/or infected with the pandemic strain. We conducted a pre-season study o...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.vaccine.2012.03.046

    authors: Langley JM,Scheifele DW,Quach C,Vanderkooi OG,Ward B,McNeil S,Dobson S,Kellner JD,Kuhn S,Kollman T,MacKinnon-Cameron D,Smith B,Li Y,Halperin SA

    更新日期:2012-05-14 00:00:00

  • Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.

    abstract::In China, no data are available to evaluate the interchangeability between Chinese domestic inactivated hepatitis A vaccines (Healive) and imported inactivated hepatitis A vaccines (Havrix). A double-blind, randomized controlled study was to compare interchangeability and safety of Healive and Havrix among Chinese chi...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2012.04.038

    authors: Zhang ZL,Zhu XJ,Wang X,Liang M,Sun J,Liu Y,Gao ZG,Wu JY,Dong XJ,Liu RK,Chen JT,Zhang YQ,Wang W,Zhang LP,Yin W

    更新日期:2012-06-08 00:00:00

  • Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.

    abstract::The carbohydrate moieties on HIV-1 envelope glycoprotein (Env) act as shields to mask conserved neutralizing epitopes, while the hyperimmunogenic variable regions are immunodominant in inducing non-neutralizing antibodies, representing the major challenge for using Env as a vaccine candidate to induce broadly neutrali...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.073

    authors: Fu M,Hu K,Hu H,Ni F,Du T,Shattock RJ,Hu Q

    更新日期:2019-12-03 00:00:00

  • Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity.

    abstract:INTRODUCTION:The World Health Organization recommends that as part of the polio end-game strategy a dose of inactivated poliovirus vaccine (IPV) be introduced by the end of 2015 in all countries currently using only oral poliovirus vaccine (OPV). Administration of fractional dose (1/5 of full dose) IPV (fIPV) by intrad...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2015.06.071

    authors: Resik S,Tejeda A,Mach O,Sein C,Molodecky N,Jarrahian C,Saganic L,Zehrung D,Fonseca M,Diaz M,Alemany N,Garcia G,Hung LH,Martinez Y,Sutter RW

    更新日期:2015-10-26 00:00:00

  • Adjuvant effect of Cliptox on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice.

    abstract::Foot and Mouth Disease (FMD) is an acute disease caused by Foot and Mouth Disease Virus (FMDV) which causes important economy losses, this is why it is necessary to obtain a vaccine that stimulates a rapid and long-lasting protective immune response. Cliptox is a mineral microparticle that in earlier studies has shown...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.06.098

    authors: Batista A,Quattrocchi V,Olivera V,Langellotti C,Pappalardo JS,Di Giacomo S,Mongini C,Portuondo D,Zamorano P

    更新日期:2010-08-31 00:00:00